SCHEMBL29535693

SCHEMBL29535693

CC(C)(C)OC(=O)N1CCC(CO)(c2ccccn2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.51
OPRD1 P41143 1/20 0.48
OPRK1 P41145 1/20 0.48
POLB P06746 1/20 0.47
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
TACR1 P25103 1/20 0.46
GRM5 P41594 1/20 0.45
CCR5 P51681 2/20 0.43
DTYMK P23919 1/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
HSD17B10 Q99714 2/20 0.43
TSHR P16473 2/20 0.43
CYP2C19 P33261 1/20 0.43
ACHE P22303 1/20 0.43
HSD11B1 P28845 1/20 0.42
ALDH1A1 P00352 1/20 0.42
ALOX15 P16050 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5472801 1.00 GPR119 (0.51) GPR119OPRD1OPRK1POLBJAK2
SCHEMBL13059786 0.91 GPR119 (0.51) GPR119OPRD1OPRK1POLBJAK2
SCHEMBL3325436 0.89 GPR119 (0.50) GPR119OPRD1OPRK1POLBJAK2
SCHEMBL20493552 0.86 OPRD1 (0.52) GPR119OPRD1OPRK1POLBJAK2
SCHEMBL30227070 0.86 OPRD1 (0.52) GPR119OPRD1OPRK1POLBJAK2
SCHEMBL1181843 0.84 GPR119 (0.54) GPR119OPRD1OPRK1POLBJAK2
SCHEMBL6888743 0.83 GPR119 (0.53) GPR119OPRD1OPRK1POLBJAK2
SCHEMBL2224318 0.83 GPR119 (0.53) GPR119OPRD1OPRK1POLBJAK2
SCHEMBL11963144 0.83 JAK2 (0.43) GPR119OPRD1OPRK1POLBJAK2
SCHEMBL5472913 0.82 GPR119 (0.52) GPR119OPRD1OPRK1POLBJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4192458-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET C4 Therapeutics, Inc. (US) 2023-06-14 EP disclosed
WO-2022032026-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET C4 THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed